Company intelligence / Profile preview

Galmed Research and Development, Ltd.

Tel Aviv, Israel

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Galmed is a clinical-stage biopharmaceutical company primarily focused on developing Aramchol, an SCD1 inhibitor, for NASH and liver fibrosis. Recent Phase 3 ARMOR study results show Aramchol's systemically active profile, with biomarker evidence of reduced inflammation, cardiac stress, and liver fibrosis. Aramchol has also shown synergy with Regorafenib in pre-clinical GI oncology studies and significant anti-fibrotic effects in PSC models.

Therapeutic areas: OncologyCardiovascularGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Proteas Health

Beyond the preview

Go deeper on Galmed Research and Development, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galmed Research and Development, Ltd..

Explore the full profile